212 related articles for article (PubMed ID: 12871067)
1. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling.
Stefansson S; McMahon GA; Petitclerc E; Lawrence DA
Curr Pharm Des; 2003; 9(19):1545-64. PubMed ID: 12871067
[TBL] [Abstract][Full Text] [Related]
2. [Role of PAI-1 plasminogen activator inhibitor in tumor invasion and angiogenesis].
Bajou K
Bull Mem Acad R Med Belg; 2002; 157(5-6):313-8. PubMed ID: 12557575
[TBL] [Abstract][Full Text] [Related]
3. [Role of plasminogen activator inhibitor type 1 in tumor angiogenesis].
Bajou K; Devy L; Masson V; Albert V; Frankenne F; Noël A; Foidart JM
Therapie; 2001; 56(5):465-72. PubMed ID: 11806282
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.
Kjøller L; Kanse SM; Kirkegaard T; Rodenburg KW; Rønne E; Goodman SL; Preissner KT; Ossowski L; Andreasen PA
Exp Cell Res; 1997 May; 232(2):420-9. PubMed ID: 9168821
[TBL] [Abstract][Full Text] [Related]
5. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies.
Bajou K; Masson V; Gerard RD; Schmitt PM; Albert V; Praus M; Lund LR; Frandsen TL; Brunner N; Dano K; Fusenig NE; Weidle U; Carmeliet G; Loskutoff D; Collen D; Carmeliet P; Foidart JM; Noël A
J Cell Biol; 2001 Feb; 152(4):777-84. PubMed ID: 11266468
[TBL] [Abstract][Full Text] [Related]
6. Endothelial cell proteases: physiological role and regulation.
Menashi S; Lu H; Soria C; Legrand Y
Baillieres Clin Haematol; 1993 Sep; 6(3):559-76. PubMed ID: 7517736
[TBL] [Abstract][Full Text] [Related]
7. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis.
Leik CE; Su EJ; Nambi P; Crandall DL; Lawrence DA
J Thromb Haemost; 2006 Dec; 4(12):2710-5. PubMed ID: 17010152
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin.
Isogai C; Laug WE; Shimada H; Declerck PJ; Stins MF; Durden DL; Erdreich-Epstein A; DeClerck YA
Cancer Res; 2001 Jul; 61(14):5587-94. PubMed ID: 11454712
[TBL] [Abstract][Full Text] [Related]
10. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
Whitley BR; Church FC
Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
[TBL] [Abstract][Full Text] [Related]
11. The plasminogen activator system and cancer.
McMahon B; Kwaan HC
Pathophysiol Haemost Thromb; 2008; 36(3-4):184-94. PubMed ID: 19176991
[TBL] [Abstract][Full Text] [Related]
12. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
Almholt K; Nielsen BS; Frandsen TL; Brünner N; Danø K; Johnsen M
Oncogene; 2003 Jul; 22(28):4389-97. PubMed ID: 12853975
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis.
McMahon GA; Petitclerc E; Stefansson S; Smith E; Wong MK; Westrick RJ; Ginsburg D; Brooks PC; Lawrence DA
J Biol Chem; 2001 Sep; 276(36):33964-8. PubMed ID: 11441025
[TBL] [Abstract][Full Text] [Related]
14. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
Gutierrez LS; Schulman A; Brito-Robinson T; Noria F; Ploplis VA; Castellino FJ
Cancer Res; 2000 Oct; 60(20):5839-47. PubMed ID: 11059781
[TBL] [Abstract][Full Text] [Related]
15. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.
Kaneko T; Konno H; Baba M; Tanaka T; Nakamura S
Cancer Sci; 2003 Jan; 94(1):43-9. PubMed ID: 12708473
[TBL] [Abstract][Full Text] [Related]
16. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
17. XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro.
Brooks TD; Wang SW; Brünner N; Charlton PA
Anticancer Drugs; 2004 Jan; 15(1):37-44. PubMed ID: 15090742
[TBL] [Abstract][Full Text] [Related]
18. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
[TBL] [Abstract][Full Text] [Related]
19. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.
Whitley BR; Palmieri D; Twerdi CD; Church FC
Exp Cell Res; 2004 Jun; 296(2):151-62. PubMed ID: 15149846
[TBL] [Abstract][Full Text] [Related]
20. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations.
Chazaud B; Ricoux R; Christov C; Plonquet A; Gherardi RK; Barlovatz-Meimon G
Am J Pathol; 2002 Jan; 160(1):237-46. PubMed ID: 11786417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]